2 results
Approved WMOPending
The primary objective is to characterize the change in the Pharmacodynamic (PD) biomarker, fecal calprotectin, during treatment with anrukinzumab.The secondary objectives include:* Characterization of the PK profile and total IL-13 of three multiple…
Approved WMORecruiting
The aim of this study is to assess the diagnostic and monitoring properties of muscle US and to investigate if US is able to distinguish a myositis flare-up from a steroid-induced myopathy.